



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Fleming et al.

Application No. 10/511,233 Filed: October 12, 2004 Confirmation No. 2272

For: ENHANCEMENT OF HEMATOPOIETIC

STEM CELL SURVIVAL

Examiner: Not yet assigned.

Art Unit: 1644

Attorney Reference No. 899-64967-07

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)___

Date Mailed February 23, 2006

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

Information Disclosure Statement

Form 1449 and one reference cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been

received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

cc: Docketing

Susan Alpert Siegel, Ph.D. Registration No. 43,121



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Fleming et al.

Application No. 10/511,233 Filed: October 12, 2004 Confirmation No. 2272

For: ENHANCEMENT OF HEMATOPOIETIC

STEM CELL SURVIVAL

Examiner: Not yet assigned.

Art Unit: 1644

Attorney Reference No. 899-64967-07

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS, P.O. BOX 1450.

ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed February 10, 2006

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith is one English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, DLP

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 595-5300

Facsimile: (503) 595-5301

Susan Alpert Siegel, Ph.D. Registration No. 43,121

613	FER 2 7 2006	& \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
· · · · · ·	A THARBANA	5/
mor (CT A TENATE	NTT.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-64967-07	
Application Number	10/511,233	
Filing Date	October 12, 2004	
First Named Inventor	Fleming	
Art Unit	1644	
Examiner Name		

	·	Danimot Tune		
Examiner's Initials*	Cite No. (optional)			
Girelli, M. et al., "Human Embryonic Endothelial Cells: A New Tool for Therap Approach in Neurological Disorders?" <i>Abstracts of the Society for Neuroscience</i> 26(1/2):327 (2000)				
		·		
:				

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
	<u></u>

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.